Inhibikase Therapeutics (IKT) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on June 26, 2026, with shareholders able to attend, vote, and submit questions online using a 12-digit control number.

• Shareholders of record as of April 27, 2026, are entitled to vote on six key proposals, including director elections, auditor ratification, amendments to the certificate of incorporation and equity plan, and advisory votes on executive compensation.

• Proxy materials are distributed via Internet access, with options for electronic or printed copies, and voting can be done online, by phone, or by mail.

Voting matters and shareholder proposals

• Proposal 1: Election of two Class III directors, Arvind Kush and Dennis Berman, to serve until 2029.

• Proposal 2: Ratification of CohnReznick LLP as independent auditor for fiscal year 2026.

• Proposal 3: Amendment to the certificate of incorporation to limit liability of certain officers as permitted by Delaware law.

• Proposal 4: Amendment to the 2020 Equity Incentive Plan to increase shares reserved for issuance by 3,000,000.

• Proposal 5: Non-binding advisory vote on executive compensation (Say-on-Pay).

• Proposal 6: Non-binding advisory vote on the frequency of future Say-on-Pay votes, with the board recommending annual votes.

Board of directors and corporate governance

• The board consists of seven members divided into three staggered classes, with only one class up for election each year.

• All non-employee directors are independent under Nasdaq and SEC rules, except the CEO.

• The board has audit, compensation, and corporate governance/nominating committees, each composed entirely of independent directors.

• The board encourages separation of the Chairperson and CEO roles to reinforce independence.

• Directors are encouraged to attend annual meetings, and all attended in 2025.